Unicycive Therapeutics, Inc. (UNCY): Submission of Matters to a Vote of Security Holders
Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001766140 0001766140 2026-06-19 2026-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
How this was made
The 30-second read
Why it matters
The disclosure confirms (1) election of three directors and (2) ratification of Grassi & Co. CPAs, P.C. as independent registered public accounting firm for the fiscal year ended December 31, 2026. No new business developments are included.
Market read
Primarily a compliance/governance update; not a catalyst for valuation or risk repricing.
What to watch
Traders may check whether any director election involved unusually high withhold votes or whether auditor ratification signals upcoming audit-related issues; however, the filing does not provide such interpretation.
Background
This is an SEC Form 8-K (Item 5.07) summarizing stockholder voting results from Unicycive Therapeutics’ annual meeting held June 19, 2026.
Ticker impact
Unicycive Therapeutics reports 8-K results from its June 19 annual meeting, including director elections and ratification of its auditor for FY2026.
Limited near-term impact; any reaction likely confined to low-liquidity governance noise rather than fundamentals.
The filing is a standard Item 5.07 disclosure of voting results (directors elected; auditor ratified) with no new guidance, trial data, financing, or enforcement action.
Market effects
None—no sector-wide regulatory, clinical, or reimbursement development is disclosed.
None—no geographic or macro linkage beyond routine SEC reporting.
None—no international transaction or cross-border regulatory action mentioned.
Counterpoint
Even routine governance filings can matter if they hint at board turnover or auditor changes, but this 8-K provides no qualitative rationale or strategic shift.
Key entities
- public_companyUnicycive Therapeutics, Inc.
Subject of the 8-K; reports annual meeting voting outcomes (director elections and auditor ratification).
- auditorGrassi & Co. CPAs, P.C.
Independent registered public accounting firm ratified by stockholders for FY2026.
- executiveDr. Shalabh Gupta
Director nominee elected at the annual meeting (as reported in the vote table).
- executiveDr. Sandeep Laumas
Director nominee elected at the annual meeting (as reported in the vote table).
- executiveD. Sarawati Kenkare-Mitra
Director nominee elected at the annual meeting (as reported in the vote table).
